Last checked at 26 Sep 2022 08:21
GSK looks to Burberry for new CFO
(Sharecast News) - GSK has named Burberry Group's Julie Brown as its new chief financial officer.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades5,869
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,583.50
Bid:
1,582.50
Ask:
1,583.00
Change:
-6.50 (-0.41%)
Spread:
0.50 (0.032%)
Open:
1,593.00
High:
1,595.50
Low:
1,580.00
Prev. Close:
1,590.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.26 Sep 2022 07:47
LONDON BRIEFING: Unilever CEO to step down; RPS backs new takeover bid
(Alliance News) - All eyes will be on the pound when traders in Europe return to desks on Monday, after the UK currency fell to an all-time low during the Asian session.
Read more24 Sep 2022 17:57
GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
Sept 24 (Reuters) - British drugmaker GSK plc has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday.
Read more24 Sep 2022 17:32
GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
Sept 24 (Reuters) - British drugmaker GSK plc, has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday.
Read more23 Sep 2022 06:57
GSK cancer drug Zejula to be reviewed by US health watchdog
(Alliance News) - GSK PLC on Thursday said its cancer drug Zejula will be reviewed by the US Food & Drug Administration for overall survival data for patients with ovarian cancer.
Read more22 Sep 2022 08:43
TOP NEWS: GSK signs licence deal for Spero's tebipenem HBr antibiotic
(Alliance News) - GSK PLC on Thursday said it has signed an exclusive licence agreement with Massachusetts-based biotechnology firm Spero Therapeutics for the latter's tebipenem pivoxil hydrobromide, or tebipenem HBr.
Read more22 Sep 2022 07:47
GSK takes stake in Spero in deal on UTI treatment
(Sharecast News) - UK pharmaceutical company GSK is taking a stake in Spero Therapeutics as part of a licensing agreement for the US-based drug developer's experimental antibiotic for complicated urinary tract infections.
Read more20 Sep 2022 10:59
TOP NEWS SUMMARY: Haleon makes positive start separate from GSK
(Alliance News) - The following is a summary of top news stories Tuesday.
Read more20 Sep 2022 09:08
TOP NEWS: Haleon makes good earnings debut with interim revenue rise
(Alliance News) - Haleon PLC on Tuesday reported a strong performance in the first half of 2022 in its first earnings report since being split from GSK PLC in July and separately listed, noting double-digit revenue growth and profit rise.
Read more20 Sep 2022 08:58
Haleon believes it is not liable for any potential Zantac liabilities
LONDON, Sept 20 (Reuters) - Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday.
Read more20 Sep 2022 07:51
LONDON BRIEFING: Haleon reports double-digit revenue growth
(Alliance News) - Stocks in London are set to open higher on Tuesday, as markets in London return to action following a bank holiday for the state funeral of Queen Elizabeth II.
Read more20 Sep 2022 07:14
Haleon rejects Zantac indemnification requests from GSK, Pfizer
LONDON, Sept 20 (Reuters) - Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.
Read more16 Sep 2022 08:16
TOP NEWS: Two AstraZeneca drugs get recommendations for EU approval
(Alliance News) - AstraZeneca PLC on Friday said it received two recommendations for drug approvals in the EU, while a drug for blood disorder paroxysmal nocturnal haemoglobinuria met its primary endpoint in a phase three trial.
Read more15 Sep 2022 23:01
WHO 'strongly advises against' use of two COVID treatments
LONDON, Sept 15 (Reuters) - Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete.
Read more15 Sep 2022 13:49
Credit Suisse upgrades GSK, downgrades AstraZeneca
(Sharecast News) - Credit Suisse upgraded GlaxoSmithKline on Thursday but downgraded AstraZeneca as it took a look at the pharmaceuticals sector.
Read more